This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Prize Contingency Management for Cocaine-Dependent Methadone Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Nancy Petry, UConn Health
ClinicalTrials.gov Identifier:
NCT01401270
First received: July 22, 2011
Last updated: June 23, 2017
Last verified: June 2017
  Purpose
The investigators will randomize 300 cocaine-dependent methadone patients to 1 of 6 conditions: (a) a control group, (b) a contingency management condition that arranges a 100% probability of winning a prize with each draw and has 3 prize categories, (c) a contingency management condition that arranges a 31% probability of winning and has 3 prize categories, (d) a contingency management condition that arranges a 100% probability of winning and has 7 prize categories, (e) a contingency management condition that arranges a 31% probability of winning and has 7 prize categories, or (f) usual prize contingency management with a 50% probability of winning from 3 prize categories. Magnitudes of reinforcement will be identical across conditions, but lower overall probability conditions arrange for greater chances of winning larger magnitude prizes. The investigators expect that the new contingency management conditions will reduce cocaine use relative to the control condition, that 31% probability conditions will decrease drug use relative to 100% conditions, and that 7-prize category conditions will reduce drug use compared to 3-prize category conditions. In addition, the 31%/7-category condition is expected to be most efficacious. Results will be instrumental for further developing prize contingency management to improve outcomes of cocaine-dependent methadone patients.

Condition Intervention
Cocaine Abuse Behavioral: prize contingency management

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Prize Contingency Management for Cocaine-Dependent Methadone Patients

Resource links provided by NLM:


Further study details as provided by Nancy Petry, UConn Health:

Primary Outcome Measures:
  • longest continuous period of cocaine abstinence [ Time Frame: three months ]

Estimated Enrollment: 300
Study Start Date: November 2011
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Treatment Group A
Standard Care
Experimental: Treatment Group B
100% probability of winning a prize with each draw and has 3 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
Experimental: Treatment Group C
31% probability of winning and has 3 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
Experimental: Treatment Group D
100% probability of winning and has 7 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
Experimental: Treatment Group E
31% probability of winning and has 7 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
Experimental: Treatment Group F
usual prize contingency management with a 50% probability of winning from 3 prize categories
Behavioral: prize contingency management
Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 18 years
  • current DSM-IV diagnosis of cocaine dependence
  • enrolled at the clinic for >3 months
  • on a stable dose of methadone (no changes) for >1 month and not requesting a dose alteration
  • submitted >1 clinic cocaine positive sample in the last 6 months
  • English speaking
  • pass a quiz related to understanding the informed consent form

Exclusion Criteria:

  • serious, uncontrolled psychiatric illness
  • significant cognitive impairment
  • in recovery from pathological gambling
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01401270

Locations
United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Sheila M Alessi, Ph.D. UConn Health
  More Information

Responsible Party: Nancy Petry, Professor, UConn Health
ClinicalTrials.gov Identifier: NCT01401270     History of Changes
Other Study ID Numbers: 10-256-2
R01DA013444 ( U.S. NIH Grant/Contract )
Study First Received: July 22, 2011
Last Updated: June 23, 2017

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Methadone
Cocaine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents
Anesthetics, Local
Anesthetics
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on July 25, 2017